Exposure to human immunodeficiency virus (HIV) type I indicated by HIV-specific T helper cell responses before detection of infection by polymerase chain reaction and serum antibodies [corrected] - PubMed (original) (raw)
Case Reports
. 1991 Jul;164(1):178-82.
doi: 10.1093/infdis/164.1.178.
Affiliations
- PMID: 1829105
- DOI: 10.1093/infdis/164.1.178
Case Reports
Exposure to human immunodeficiency virus (HIV) type I indicated by HIV-specific T helper cell responses before detection of infection by polymerase chain reaction and serum antibodies [corrected]
M Clerici et al. J Infect Dis. 1991 Jul.
Erratum in
- J Infect Dis 1991 Oct;164(4):832
Abstract
A healthy individual at risk for human immunodeficiency virus type 1 (HIV-1) infection was studied longitudinally for 19 months for evidence of exposure to and infection with HIV. Peripheral blood mononuclear cells (PBMC) were tested at 1, 5, 13, 16, and 19 months for T helper (Th) cell function by in vitro-generated proliferation and interleukin-2 production in response to four synthetic peptides corresponding to env of HIV. PBMC were also tested for proviral DNA using gag primers by the polymerase chain reaction (PCR) at 0, 5, 10, 13, 16, and 19 months. HIV serology by ELISA and p24 antigen and Western blot analyses were done on samples taken at 0, 1, 5, 10, 13, 16, and 19 months. The results indicated that both Th cell tests were positive during months 5-19. In contrast, the PCR and all serologic assays were negative except for month 19, when the assays became positive. These results, based on the longitudinal study of one individual, showed that the Th cell tests can reveal exposure to HIV-1 antigens several months before evidence of viral infection is detected, even by PCR.
Similar articles
- HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood.
Clerici M, Levin JM, Kessler HA, Harris A, Berzofsky JA, Landay AL, Shearer GM. Clerici M, et al. JAMA. 1994 Jan 5;271(1):42-6. JAMA. 1994. PMID: 8258885 - Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1.
Clerici M, Giorgi JV, Chou CC, Gudeman VK, Zack JA, Gupta P, Ho HN, Nishanian PG, Berzofsky JA, Shearer GM. Clerici M, et al. J Infect Dis. 1992 Jun;165(6):1012-9. doi: 10.1093/infdis/165.6.1012. J Infect Dis. 1992. PMID: 1533867 - Early induction and maintenance of Env-specific T-helper cells following human immunodeficiency virus type 1 infection.
Malhotra U, Holte S, Zhu T, Delpit E, Huntsberry C, Sette A, Shankarappa R, Maenza J, Corey L, McElrath MJ. Malhotra U, et al. J Virol. 2003 Feb;77(4):2663-74. doi: 10.1128/jvi.77.4.2663-2674.2003. J Virol. 2003. PMID: 12552005 Free PMC article. - Laboratory methods in the diagnosis and prognostic staging of infection with human immunodeficiency virus type 1.
Davey RT Jr, Lane HC. Davey RT Jr, et al. Rev Infect Dis. 1990 Sep-Oct;12(5):912-30. doi: 10.1093/clinids/12.5.912. Rev Infect Dis. 1990. PMID: 2237133 Review. - Immune response to human immunodeficiency virus (HIV) in healthcare workers occupationally exposed to HIV-contaminated blood.
Pinto LA, Landay AL, Berzofsky JA, Kessler HA, Shearer GM. Pinto LA, et al. Am J Med. 1997 May 19;102(5B):21-4. doi: 10.1016/s0002-9343(97)00056-9. Am J Med. 1997. PMID: 9845492 Review.
Cited by
- Exposed seronegative: Cellular immune responses to SARS-CoV-2 in the absence of seroconversion.
Jay C, Ratcliff J, Turtle L, Goulder P, Klenerman P. Jay C, et al. Front Immunol. 2023 Jan 26;14:1092910. doi: 10.3389/fimmu.2023.1092910. eCollection 2023. Front Immunol. 2023. PMID: 36776841 Free PMC article. Review. - Involvement of neutrophil hyporesponse and the role of Toll-like receptors in human immunodeficiency virus 1 protection.
Hernandez JC, Giraldo DM, Paul S, Urcuqui-Inchima S. Hernandez JC, et al. PLoS One. 2015 Mar 18;10(3):e0119844. doi: 10.1371/journal.pone.0119844. eCollection 2015. PLoS One. 2015. PMID: 25785697 Free PMC article. - An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection.
Hemachandra A, Puls RL, Sirivichayakul S, Kerr S, Thantiworasit P, Ubolyam S, Cooper DA, Emery S, Phanuphak P, Kelleher A, Ruxrungtham K. Hemachandra A, et al. Hum Vaccin. 2010 Oct;6(10):835-40. doi: 10.4161/hv.6.10.12635. Epub 2010 Oct 1. Hum Vaccin. 2010. PMID: 20864808 Free PMC article. Clinical Trial. - Persistently HIV-1 seronegative Nairobi sex workers are susceptible to in vitro infection.
Bienzle D, Macdonald KS, Copeland KF, Bwayo JJ, Plummer FA, Rosenthal KL. Bienzle D, et al. Can J Infect Dis. 2000 Sep;11(5):259-63. doi: 10.1155/2000/390310. Can J Infect Dis. 2000. PMID: 18159299 Free PMC article. - Low maternal viral loads and reduced granulocyte-macrophage colony-stimulating factor levels characterize exposed, uninfected infants who develop protective human immunodeficiency virus type 1-specific responses.
Schramm DB, Meddows-Taylor S, Gray GE, Kuhn L, Tiemessen CT. Schramm DB, et al. Clin Vaccine Immunol. 2007 Apr;14(4):348-54. doi: 10.1128/CVI.00464-06. Epub 2007 Feb 14. Clin Vaccine Immunol. 2007. PMID: 17301218 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical